Since any systemic therapy targeting NRP2 would block its function not only in osteoclasts but also in other myeloid cells, we expect our syngeneic mouse model simulates use of an NRP2 inhibitor to treat PCa bone metastasis. This evidence concerns the gene NRP2 and posterior cortical atrophy.